{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:33:24Z","timestamp":1768012404242,"version":"3.49.0"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tenofovir alafenamide fumarate (TAF) has high plasma stability resulting in fewer renal adverse events compared to tenofovir disoproxil fumarate (TDF) in chronic hepatitis B (CHB) patients. We aimed to study the effectiveness and renal safety of TAF in a real\u2010world setting, in patients with or without compromised kidney function. CHB patients (Nucleos(t)ide Analogue [NA]\u2010na\u00efve or experienced) who received TAF &gt;1\u00a0year from 11 academic institutions as part of the Canadian Hepatitis B Network (CanHepB) were included. Kidney function was measured by estimated glomerular filtration rate (eGFR) as per Cockcroft\u2010Gault. Patients were followed for up to 160\u00a0weeks. Of 176 patients receiving TAF, 143 switched from NA (88% TDF), and 33(19%) were NA na\u00efve. Majority of NA\u2010na\u00efve patients (75%) achieved undetectable HBV DNA after one year of TAF treatment. Majority of patients with eGFR &lt;60\u00a0mL\/min who had renal deterioration during TDF (76%) reversed to eGFR increase after one year of TAF (<jats:italic>p<\/jats:italic>=0.009). Among patients with stage 2 chronic kidney disease (CKD) (eGFR 60\u201389), the estimated eGFR decline during TDF was halted after switching to TAF (<jats:italic>p<\/jats:italic>=0.09). NA\u2010experienced patients with abnormal ALT before TAF showed a significant decline after switching to TAF: \u22120.005 [\u22120.006 \u2013 \u22120.004] log<jats:sub>10<\/jats:sub> ULN U\/L\/month, <jats:italic>p<\/jats:italic>&lt;0.001). In CHB patients, TAF was safe, well\u2010tolerated and effective in this real\u2010world cohort. Switching to TAF led to improved kidney function, particularly in those with stage 2 CKD, which suggests that the indication for TAF in the guidelines could be extended to patients with an eGFR higher than 60\u00a0mL\/min.<\/jats:p>","DOI":"10.1111\/jvh.13500","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T08:11:14Z","timestamp":1616400674000},"page":"942-950","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real\u2010World Study"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1579-1680","authenticated-orcid":false,"given":"Mina S.","family":"Farag","sequence":"first","affiliation":[{"name":"Toronto Centre for Liver Disease Toronto General Hospital University Health Network Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Fung","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease Toronto General Hospital University Health Network Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Tam","sequence":"additional","affiliation":[{"name":"Canadian Hepatitis B Network Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Doucette","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases University of Alberta Edmonton Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Wong","sequence":"additional","affiliation":[{"name":"Regina Health Region Regina Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alnoor","family":"Ramji","sequence":"additional","affiliation":[{"name":"Gastroenterology Division St Paul's Hospital Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Conway","sequence":"additional","affiliation":[{"name":"Vancouver Infectious Diseases Centre Vancouver Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3368-3499","authenticated-orcid":false,"given":"Curtis","family":"Cooper","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Ottawa Ottawa Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Tsoi","sequence":"additional","affiliation":[{"name":"Department of Medicine McMaster University Hamilton Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Wong","sequence":"additional","affiliation":[{"name":"McGill University Montreal Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giada","family":"Sebastiani","sequence":"additional","affiliation":[{"name":"McGill University Montreal Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayur","family":"Brahmania","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology Western University London Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4081-870X","authenticated-orcid":false,"given":"Sarah","family":"Haylock\u2010Jacobs","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Cumming School of Medicine University of Calgary Calgary Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1472-0901","authenticated-orcid":false,"given":"Carla S.","family":"Coffin","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Cumming School of Medicine University of Calgary Calgary Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease Toronto General Hospital University Health Network Toronto Canada"},{"name":"Institute of Health Policy, Management and Evaluation University of Toronto Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease Toronto General Hospital University Health Network Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,4]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.1.65"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.016"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.06.015"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"issue":"3","key":"e_1_2_11_8_1","first-page":"185","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg\u2010positive chronic hepatitis B virus infection: a randomised, double\u2010blind, phase 3, non\u2010inferiority trial.lancet","volume":"1","author":"Chan HLY","year":"2016","journal-title":"Gastroenterol Hepatol"},{"issue":"3","key":"e_1_2_11_9_1","first-page":"196","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg\u2010negative chronic hepatitis B virus infection: a randomised, double\u2010blind, phase 3, non\u2010inferiority trial.lancet","volume":"1","author":"Buti M","year":"2016","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00348-5"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.039"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)31347-8"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30312-4"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14686"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13053"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.192644"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.3138\/canlivj.2018-0008"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.01.416"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.20748"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00128-15"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001466"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328351f68f"},{"key":"e_1_2_11_23_1","unstructured":"Administration UF D.Prescribing information for vemlidy(tenofovir alafenamide).2016."},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30421-2"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0897190012465986"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.035"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13500","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.13500","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T10:07:44Z","timestamp":1693562864000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1111\/jvh.13500"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13500","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"2021-01-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}